Inflammation and Regeneration
Online ISSN : 1880-8190
Print ISSN : 1880-9693
Mini Review
JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug
Kunihiro YamaokaSatoshi KuboKoshiro SonomotoKeisuke MaeshimaYoshiya Tanaka
Author information

Volume 31 (2011) Issue 4 Pages 349-353

Download PDF (119K) Contact us

Treatment of rheumatoid arthritis (RA) with biologic agents targeting inflammatory cytokines and cell surface molecules such as tumor necrosis factor and Interleukin-6 is generally more efficacious than traditional disease-modifying antirheumatic drugs when combined with MTX. However, not only do ∼30% of patients poorly respond to treatment but also parenteral mode of administration and expense are issues to be solved. Recently, a kinase inhibitor targeting Janus kinases (JAKs), has shown high efficacy in active RA in clinical trials. Among several JAK inhibitors in clinical trials for RA, tofacitinib is a step ahead for use in clinical practice. Kinase inhibitors are orally available, which is a major advantage over biologic agents, in addition to being less expensive. This review describes recent advance in JAK inhibitors for RA and its possible mechanism of action.

Information related to the author
© The Japanese Society of Inflammation and Regeneration
Previous article Next article

Recently visited articles